No Data
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
Maxim Group Maintains Artelo Biosciences(ARTL.US) With Buy Rating, Maintains Target Price $5
Artelo Biosciences Reports Q3 2024 Financials and Progress
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
Express News | Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13TH Annual Musculoskeletal Repair and Regeneration Symposium
H.C. Wainwright Maintains Artelo Biosciences(ARTL.US) With Buy Rating, Maintains Target Price $5
No Data
No Data